Literature DB >> 26985304

Potential Use of Inhibitors of Tankyrases and PARP-1 as Treatment for Cancer and Other Diseases.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2016        PMID： 26985304      PMCID： PMC4789656          DOI： 10.1021/acsmedchemlett.6b00017

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  3 in total

Review 1.  Tankyrase inhibitors as therapeutic targets for cancer.

Authors:  Ahmed Kamal; Sd Riyaz; Ajay Kumar Srivastava; Abdul Rahim
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 2.  Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review.

Authors:  Michael Buege; Pramod B Mahajan
Journal:  Rev Recent Clin Trials       Date:  2015

3.  Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?

Authors:  Michael O Hottiger
Journal:  Expert Opin Ther Targets       Date:  2015-07-27       Impact factor: 6.902
  3 in total
  1 in total

1.  SSRP1 Cooperates with PARP and XRCC1 to Facilitate Single-Strand DNA Break Repair by Chromatin Priming.

Authors:  Ying Gao; Changling Li; Leizhen Wei; Yaqun Teng; Satoshi Nakajima; Xiukai Chen; Jianquan Xu; Brittany Leger; Hongqiang Ma; Stephen T Spagnol; Yong Wan; Kris Noel Dahl; Yang Liu; Arthur S Levine; Li Lan
Journal:  Cancer Res       Date:  2017-04-17       Impact factor: 12.701
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.